NCT05097014已完成4 期
A Double Blind, Multicentre, Randomised, Placebo-Controlled, 3-Way Cross-Over Study To Evaluate The Effect Of A Triple Combination Of Beclometasone Dipropionate And Formoterol Fumarate Plus Glycopyrronium (CHF5993) And A Dual Combination Of Beclometasone Dipropionate Plus Formoterol Fumarate (CHF1535) Both Administered Via pMDI On Lung Hyperinflation And Exercise Endurance Time In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 106
- 试验地点
- 1
- 主要终点
- Inspiratory capacity (IC) prior to Constant Work Rate Cycle Ergometry (CWRCE) test
研究概览
简要总结
Double Blind, Multinational, Multicentre, Randomised, Placebo-Controlled, 3-Way Cross-Over Study To Evaluate The Effect Of A Triple Combination Of Beclometasone Dipropionate And Formoterol Fumarate Plus Glycopyrronium (CHF5993) And A Dual Combination Of Beclometasone Dipropionate Plus Formoterol Fumarate (CHF1535) Both Administered Via pMDI On Lung Hyperinflation And Exercise Endurance Time In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A signed and dated written informed consent obtained prior to any study-related procedures.
- •Outpatient population.
- •Male or female subjects.
- •COPD diagnosis for at least 12 months before the Screening visit in accordance with the definition by the GOLD 2020 report.
- •Current or ex-smokers (who quit smoking for at least 6 months prior to Screening Visit) with a smoking history of at least 10 pack-years [pack-years = (number of cigarettes per day x number of years)/20]. E-cigarettes smoking cannot be used to calculate pack-year history.
- •A post-bronchodilator FEV1/FVC < 0.7 within 30 min after 4 puffs (4 x 100 µg) of salbutamol pMDI and a post-bronchodilator FEV1 ≥ 40% and <80% of the predicted normal values. If this is not met at screening, the test can be repeated once before randomisation.
- •Pre-bronchodilator functional residual capacity (FRC) of > 120% of predicted normal FRC values at Screening visit
- •If this criterion is not met at screening, the test can be repeated once before randomisation.
- •A score of >2 on the Modified Medical Research Council Dyspnea Scale (mMRC) at Visit
- •Subjects on mono- or dual inhaled maintenance COPD treatment at a stable dose for at least 3 months prior to screening.
- •A cooperative attitude and ability to correctly use the study inhalers.
- •Female subjects must be women either of non-childbearing potential (WONCBP) defined as physiologically incapable of becoming pregnant (i.e. post-menopausal or permanently sterile) or physiologically capable of becoming pregnant (i.e. women of childbearing potential (WOCBP)).
- •Inclusion criteria assessed prior to Randomization:
- •CWRCE at Visit 1b: between 2 min and 11 min at 80% of maximum workload. In case the subject cycles for a shorter (i.e. < 2 min) or longer (i.e. > 11 min) period, the visit can be repeated with an adjusted workload once within a 1-week period.
- •Oxygen saturation (SpO2 measured by pulse oximeter) at least 82% during the incremental exercise test (IET) performed in the run-in period.
- •Subjects must be able to complete CWRCE at Visit 1b and then at Visit 2 without requirement for supplemental oxygen.
排除标准
- •Pregnant or lactating women.
- •Known respiratory disorders other than COPD which may impact the efficacy of the study drug according the investigator's judgment. This can include but is not limited to current diagnosis of asthma, alfa-1 antitrypsin deficiency, active tuberculosis, lung cancer, severe bronchiectasis unrelated to COPD, sarcoidosis, lung fibrosis, pulmonary hypertension and interstitial lung disease.
- •Unstable concurrent disease: e.g. fever, uncontrolled hyperthyroidism, uncontrolled diabetes mellitus or other endocrine disease; significant hepatic impairment; significant renal impairment; uncontrolled gastrointestinal disease (e.g. active peptic ulcer); uncontrolled cardiac disease, uncontrolled neurological disease; uncontrolled haematological disease; uncontrolled autoimmune disorders, or other which may impact the efficacy or the safety of the study drug according to investigator's judgment.
- •Moderate (requiring prescriptions of systemic corticosteroids and/or antibiotics) or severe (leading to hospitalization) COPD exacerbation in the 3 and 12 months, respectively, prior to Screening visit 1 and during the run-in period.
- •Subjects requiring long term (> 15 hours a day) oxygen therapy for chronic hypoxemia.
- •Subjects who have clinically severe cardiovascular condition (such as but not limited to unstable ischemic heart disease, NYHA Class IV, left ventricular failure, myocardial infarction in the prior 6 months, not controlled arrhythmia etc.), which may impact the efficacy or the safety of the study drug according to the investigator's judgement.
- •An abnormal and clinically significant 12-lead electrocardiogram (ECG) which may impact the safety of the subject according to investigator's judgement. Subjects whose 12-lead ECG shows QTcF >450 ms for males or QTcF >470 ms for females at screening visit are not eligible.
- •History of hypersensitivity to M3 receptor antagonists, β2-agonist, corticosteroids or any of the excipients contained in any of the formulations used in the trial which may raise contra-indications or impact the efficacy of the study drug according to the investigator's judgement.
- •Subjects with serum potassium levels ≤ 3.5 mEq/L (or 3.5 mmol/L)
- •Subjects with body mass index less than 15 or greater than 35 kg/m
- •History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening visit.
- •Subjects with contraindications to cardiopulmonary exercise testing, including those whose exercise test is limited by non-respiratory or cardiovascular condition, e.g. by neurologic, orthopaedic, or other disorders.
- •Participation in another clinical trial where investigational drug was received less than 30 days or 5 half-lives whichever is longer prior to screening visit.
研究组 & 干预措施
CHF5993
Active Comparator
pMDI fixed combination product of beclometasone dipropionate (BDP) 100 µg plus 6 µg of formoterol fumarate (FF) and 10 µg of glycopyrronium (G)
干预措施: CHF5993 (Drug)
CHF1535
Active Comparator
pMDI fixed combination product beclometasone dipropionate (BDP) 100 µg plus 6 µg of formoterol fumarate (FF)
干预措施: CHF1535 (Drug)
Matched placebo
Placebo Comparator
Matched placebo pMDI
干预措施: Matched placebo (Other)
结局指标
主要结局
Inspiratory capacity (IC) prior to Constant Work Rate Cycle Ergometry (CWRCE) test
时间窗: 3 weeks of treatment
Change from baseline in 2-hour post-dose
次要结局
- Exercise endurance time (EET)(3 weeks of treatment)
- IC at Isotime, defined as the shortest CWRCE test duration among baseline and end of treatment period.(3 weeks of treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisNCT05178810Ferrer Internacional S.A.300
终止
2 期
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With DementiaAgitationDementiaNCT05276830BioXcel Therapeutics Inc5
终止
3 期
Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's PatientsIdiopathic Parkinson's DiseaseNCT02453386Biotie Therapies Inc.449
已完成
3 期
Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled AsthmaAsthmaNCT03347279AstraZeneca1,061
已完成
3 期
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DMType 2 Diabetes MellitusNCT05814406JW Pharmaceutical196